Evidence map›Paper›PMID 38681104›Full record

ArticleThe Pan African medical journal2024

Acute-onset chronic inflammatory demyelinating polyneuropathy following AstraZeneca COVID-19 vaccine: a case report.

Emna Smaoui, Khadija Sonda Moalla, Nadia Bouattour, Nouha Farhat, Salma Sakka, Sawsan Daoud, Mariem Damak, Chokri Mhiri

Abstract readCase Reports
In one paragraph

Article in The Pan African medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emna SmaouiNeurology Department, Habib Bourguiba Hospital, Sfax, Tunisia.
Khadija Sonda MoallaNeurology Department, Habib Bourguiba Hospital, Sfax, Tunisia.
Nadia BouattourNeurology Department, Habib Bourguiba Hospital, Sfax, Tunisia.
Nouha FarhatNeurology Department, Habib Bourguiba Hospital, Sfax, Tunisia.
Salma SakkaNeurology Department, Habib Bourguiba Hospital, Sfax, Tunisia.
Sawsan DaoudNeurology Department, Habib Bourguiba Hospital, Sfax, Tunisia.
Mariem DamakNeurology Department, Habib Bourguiba Hospital, Sfax, Tunisia.
Chokri MhiriNeurology Department, Habib Bourguiba Hospital, Sfax, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 vaccination side effects have been increasingly reported, including new-onset autoimmune diseases such as chronic arthritis, thrombocytopenia, Guillain-Barré syndrome (GBS), and more recently chronic inflammatory demyelinating polyneuropathies (CIDP). Molecular mimicry and vaccine adjuvants appear to be important contributors to immune-mediated neuropathies. However, whether the link between the COVID-19 vaccine and these autoimmune disorders is coincidental or causal remains uncertain. We describe the ever-reported case of acute-onset CIDP following the Oxford/AstraZeneca vaccine in Tunisia. The patient is a 41-year-old man who presented with acute, worsening weakness of the four limbs. The symptoms appeared 15 days after his first dose of the AstraZeneca vaccine. The diagnosis of GBS was initially confirmed according to the clinical features, the albumino-cytological dissociation in the cerebrospinal fluid (CSF), and the electroneuromyography (ENMG) findings. Serum workup for all known infections associated with immune-mediated neuropathy was negative. The patient was treated with plasma exchange without initial improvement followed by aggravation of the symptomatology after an interval of four and a half months. Control ENMG showed signs of CIDP meeting the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria of 2021. The patient was treated with maintenance intravenous immunoglobulin and oral corticosteroids. Neurological examination 3 months after discharge showed partial improvement. Worldwide, cases of demyelinating polyneuropathies post-COVID-19 vaccination are increasingly reported. The acute onset of CIDP might lead to a misdiagnosis of GBS. Awareness of this complication and distinction from GBS enables early relay with maintenance treatment to prevent relapses and severe complications. Post-COVID neuropathies are found to be more frequently linked to the AstraZeneca vaccine, however, temporal association does not confirm causal association.

Indexed as

COVID-19 VaccinesPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingAdultChAdOx1 nCoV-19COVID-19HumansMaleTunisiaChAdOx1 nCoV-19COVID-19 VaccinesAstraZenecacase reportChronic inflammatory demyelinating polyneuropathyCOVID-19 vaccine

Identifiers

PMID38681104
PMCPMC11055180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.